P958: REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY

Documenti analoghi

• P958: REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY
  di: H. Einsele, et al.
  Pubblicazione: (2022-06-01)
• P904: LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL-LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA– FINAL ANALYSIS AT 2-YEAR FOLLOW-UP
  di: Philippe Moreau, et al.
  Pubblicazione: (2023-08-01)
• P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA
  di: K. Weisel, et al.
  Pubblicazione: (2022-06-01)
• P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
  di: Philippe Moreau, et al.
  Pubblicazione: (2023-08-01)
• P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
  di: Hermann Einsele, et al.
  Pubblicazione: (2023-08-01)